Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGiO: Adoptive Cellular Therapy for Recurrent Oligodendroglioma
NCT06254326Phase 1Recruiting
- Sponsor
- University of Florida
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TTRNA-DC vaccine and TTRNA-xALT in Oligodendroglioma (OG), sponsored by University of Florida. Primary endpoints: Prevalence of enrolled subject who receive qualified immunotherapy investigational product at 9 months and Incidence of investigational treatment related severe toxicity (Dose-limiting toxicity event) at 9 months. Started Sep 2024; status: recruiting.
02
Drugs
TTRNA-DC vaccineTTRNA-xALT
03
Conditions
Oligodendroglioma (OG)
Beyond the preview
Go deeper on NCT06254326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254326.